NCT05846009View on ClinicalTrials.gov

A First-in-human Single and Repeated Dose Escalation Study of SAR442501 in Healthy Adults Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

November 18, 2020

Primary Completion Date

January 12, 2022

Study Completion Date

January 12, 2022

Conditions
Osteochondrodysplasia
Interventions
DRUG

SAR442501

Subcutaneous injection

DRUG

Placebo

Subcutaneous injection

Trial Locations (1)

07103

Investigational site, Newark

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY